Episode 63
Biotech Hangout
00:00
The IPO Market Is Starting to Reach That Phase Again
Replimune has a big binary phase three coming up in the third quarter which might bring the whole oncolytic virus field back into favor. We had a small deal with Lilly and Virv this week and also some data from Intelliak. Can you cover those two? Yes so the Lilly Virv deal involved a gene editing approach to help people to lay. The Car P company that spun out of Bluebird and they have a car t-trial for pediatric AML and sadly they announced a patient death.
Transcript
Play full episode
